{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-068958","form_type":"8-K","ticker":"VYGR","cik":"0001640266","company_name":"Voyager Therapeutics, Inc.","filed_at":"2022-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.590069+00:00","generated_at":"2026-06-25T03:58:35.557276+00:00","sec_items":["5.02","5.07","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Voyager Therapeutics interim CSO Glenn Pierce resigns as planned, enters consulting agreement; shareholders re-elect him","bullets":["Glenn Pierce resigned as Interim CSO effective June 2, 2022, after serving in the role since June 2021 on a part-time basis.","On June 6, Pierce signed a consulting agreement with Voyager capped at $120,000, valid until June 5, 2023, for transition services.","At the June 6 annual meeting, Pierce was re-elected as Class I director with 21,014,996 votes (88.9% of votes cast).","Shareholders approved say-on-pay with 23,447,480 votes and ratified Ernst & Young as auditor with 30,505,725 votes.","Todd Carter, SVP Research, assumed increased R&D responsibilities starting June 3, reporting to CEO; search for a CSO is underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-068958","json":"https://secwatch.observer/filing/0001104659-22-068958.json","markdown":"https://secwatch.observer/filing/0001104659-22-068958.md","text":"https://secwatch.observer/filing/0001104659-22-068958.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922068958/0001104659-22-068958-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922068958/tm2217868d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T03:58:35.557276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a17b59881a","claim":"Glenn Pierce resigned as Interim Chief Scientific Officer at Voyager Therapeutics, Inc..","evidence_excerpt":"On June 2, 2022, Glenn Pierce, M.D., Ph.D. provided notice to Voyager Therapeutics, Inc. (“Voyager”) of his resignation as Interim Chief Scientific Officer, effective immediately (the “Pierce Transition”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922068958/0001104659-22-068958-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Interim Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}